Maertens JA, Rahav G, Lee DG, et al. - Researchers undertook this randomised, prospective, double-blind, double-dummy, controlled trial to evaluate non-inferiority of posaconazole to voriconazole for the primary treatment of invasive aspergillosis. Participants were patients with age 13 years or older, weight at least 40 kg, and who satisfied criteria for proven, probable, or possible fungal disease. Posaconazole (intravenous or oral posaconazole 300 mg twice on day 1, followed by 300 mg once a day for days 2–84) was compared with voriconazole (6 mg/kg intravenous or 300 mg oral twice on day 1 followed by 4 mg/kg intravenously or 200 mg orally twice a day for days 2–84) for 12 weeks or less. Findings demonstrated the non-inferiority of posaconazole to voriconazole with respect to all-cause mortality up until day 42 in patients suffering from invasive aspergillosis. Good tolerability of posaconazole was reported, and fewer treatment-related adverse events were experienced by patients vs in the voriconazole group. Thus, posaconazole use as a first-line treatment for the condition is supported.